netFormulary NHS
North Staffordshire Joint Formulary
North Staffordshire Clinical Commissioning Group
Stoke-on-Trent Clinical Commissioning Group
 Search
 Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
Notes:

For the most up to date list of agents funded by the Cancer Drugs Fund, please see Cancer Drug Fund List

The list should be read in conjunction with Appraisal and Funding of Cancer Drugs from July 2016 (including the new Cancer Drugs Fund).

 Details...
08.01.05  Expand sub section  Other antineoplastic drugs
Cytotoxic Drug Hydroxycarbamide 
(Hydrea®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber
 
   
Abemaciclib (Verzenios®)Black Triangle
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
NHS England

Restriction: In line with NICE guidance only

 
Link  NICE TA563: Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Link  NICE TA579: Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy
   
Cytotoxic Drug Afatinib dimaleate (Giotrif®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
NHS England

Restriction: In line with NICE Guidance only

 
Link  NICE TA310: Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer
   
Cytotoxic Drug Alectinib hydrochloride
(Alecensa®)Black Triangle
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund

Restriction: In line with NICE Guidance only

 
Link  NICE TA536: Alectinib for untreated ALK-positive advanced non-small-cell lung cancer
   
Cytotoxic Drug Arsenic trioxide (Trisenox®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund

Restriction: In line with NICE Guidance only

 
Link  NICE TA526: Arsenic trioxide for treating acute promyelocytic leukaemia
   
Cytotoxic Drug Atezolizumab (Tecentriq®)Black Triangle
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund

Restriction: In line with NICE Guidance only

 
Link  NICE TA492: Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
Link  NICE TA520 : Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy
Link  NICE TA525: Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
Link  NICE TA584: Atezolizumab in combination for treating metastice non-squamous non-small-cell lung cancer
   
Cytotoxic Drug Avelumab (Bavencio®)Black Triangle
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund

Restriction: In line with NICE Guidance only

 
Link  NICE TA517: Avelumab for treating metastatic Merkel cell carcinoma
   
Cytotoxic Drug Axitinib (Inlyta®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
NHS England

Restriction: In line with NICE Guidance only

 
Link  NICE TA333: Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment
   
Cytotoxic Drug Bortezomib (Velcade®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England

Restriction: In line with NICE Guidance only

 
Link  NICE TA129: Bortezomib monotherapy for relapsed multiple myeloma
Link  NICE TA228: Bortezomib and thalidomide for the first‑line treatment of multiple myeloma
Link  NICE TA311: Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation
Link  NICE TA370: Bortezomib for previously untreated mantle cell lymphoma
Link  NICE TA573: Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma
   
Cytotoxic Drug Bosutinib (Bosulif®)Black Triangle
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England

Restriction: In line with NICE Guidance only

 

MHRA/CHM advice (May 2016): Risk of hepatitis B virus reactivation with BCR-ABL tyrosine kinase inhibitors

 
Link  NICE TA401: Bosutinib for previously treated chronic myeloid leukaemia
   
Cytotoxic Drug Brentuximab vedotin
(Adcetris®)Black Triangle
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England

Restriction: In line with NICE Guidance only

 
Link  NICE TA478: Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma
Link  NICE TA524: Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma
Link  NICE TA577: Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma
   
Brigatinib (Alunbrig®)Black Triangle
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
NHS England

Restriction: In line with NICE guidance only

 
Link  NICE TA571: Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib
   
Cytotoxic Drug Cabazitaxel (Jevtana®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England

Restriction: In line with NICE Guidance only

 
Link  NICE TA391: Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel
   
Cytotoxic Drug Cabozantinib (Cabometyx®)Black Triangle
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England

Restriction: In line with NICE Guidance only

 
Link  NICE TA463: Cabozantinib for previously treated advanced renal cell carcinoma
Link  NICE TA516: Cabozantinib for treating medullary thyroid cancer
Link  NICE TA542: Cabozantinib for untreated advanced renal cell carcinoma
   
Cytotoxic Drug Carfilzomib (Kyprolis®)Black Triangle
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England

Restriction: In line with NICE Guidance only

 

MHRA advice (Aug 2019): Carfilzomib (Kyprolis▼)- reminder of risk of potentially fatal cardiac events

 
Link  NICE TA457 : Carfilzomib for previously treated multiple myeloma
   
Cytotoxic Drug Cemiplimab (Libtayo®)Black Triangle
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England

Restriction: In line with NICE Guidance only

 
Link  NICE TA592: Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma
   
Cytotoxic Drug Ceritinib (Zykadia®)Black Triangle
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England

Restriction: In line with NICE Guidance only

 
Link  NICE TA395: Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer
Link  NICE TA500: Ceritinib for untreated ALK-positive non-small-cell lung cancer
   
Cytotoxic Drug Cetuximab (Erbitux®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England

Restriction: In line with NICE Guidance only

 
Link  NICE TA145: Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck
Link  NICE TA439 : Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
Link  NICE TA473: Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck
   
Cytotoxic Drug Crizotinib (Xalkori®)Black Triangle
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England

Restriction: In line with NICE Guidance only

 

MHRA/CHM advice (November 2015): Risk of cardiac failure

 
Link  NICE TA406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
Link  NICE TA422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cance
Link  NICE TA529: Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer
   
Cytotoxic Drug Dabrafenib mesilate
(Tafinlar®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England

Restriction: In line with NICE Guidance only

 
Link  NICE TA321:Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma
Link  NICE TA396:Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
Link  NICE TA544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma
   
Dacomitinib (Vizimpro®)Black Triangle
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
NHS England

Restriction: In line with NICE Guidance only

 
Link  NICE TA595: Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer
   
Cytotoxic Drug Daratumumab (Darzalex®)Black Triangle
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England

Restriction: In line with NICE Guidance only

 

MHRA advice (Aug 2019): Daratumumab (Darzalex▼)- risk of reactivation of hepatitis B virus

 
Link  NICE TA510: Daratumumab monotherapy for treating relapsed and refractory multiple myeloma
Link  NICE TA573: Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma
   
Cytotoxic Drug Dasatinib (Sprycel®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England

Restriction: In line with NICE Guidance only

 
Link  NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Link  NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
   
Cytotoxic Drug Dinutuximab beta (Qarziba®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund

Restriction: In line with NICE Guidance only

 
Link  NICE TA538: Dinutuximab beta for treating neuroblastoma
   
Cytotoxic Drug Docetaxel 
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine

Restriction: In line with NICE Guidance only

 
Link  NICE NG101: Early and locally advanced breast cancer: diagnosis and management
Link  NICE TA101: Prostate cancer (hormone-refractory) - docetaxel
Link  NICE TA109: Breast cancer (early) - docetaxel
   
Cytotoxic Drug Doxorubicin hydrochloride
(Caelyx®)
(Liposomal pegylated)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England

Restriction: In line with NICE Guidance only

 
Link  NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
   
Durvalumab (Imfinzi®)Black Triangle
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
NHS England

Restriction: In line with NICE Guidance only

 
Link  NICE TA578: Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation
   
Encorafenib  (Braftovi®)Black Triangle
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
NHS England

Restriction: In line with NICE guidance only

 
Link  NICE TA562: Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma
   
Cytotoxic Drug Eribulin (Halaven®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England

Restriction: In line with NICE Guidance only

 
Link  NICE TA423: Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens
Link  NICE TA515: Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen
   
Cytotoxic Drug Erlotinib hydrochloride
(Tarceva® )
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
NHS England

Restriction: In line with NICE Guidance only

 

Epidermal growth factor receptor (EGFR) inhibitors: serious cases of keratitis and ulcerative keratitis (May 2012)

 
Link  NICE TA227: Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer
Link  NICE TA258: Erlotinib for the first-line treatment of locally advanced metastatic EGFR-TK mutation-positive non-small-cell lung cancer
Link  NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
   
Cytotoxic Drug Everolimus 
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
NHS England

Restriction: In line with NICE Guidance only

 
Link  NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
Link  NICE TA432: Everolimus for advanced renal cell carcinoma after previous treatment
Link  NICE TA449 : Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
Link  NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
   
Cytotoxic Drug Gefitinib (Iressa®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
NHS England

Restriction: In line with NICE Guidance only

 

MHRA/CHM advice: Epidermal growth factor receptor (EGFR) inhibitors: serious cases of keratitis and ulcerative keratitis (May 2012)

 
Link  NICE TA192: Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer
Link  NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
   
Cytotoxic Drug Gemtuzumab ozogamicin
(Mylotarg®)Black Triangle
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England

Restriction: In line with NICE Guidance only

 
Link  NICE TA545: Gemtuzumab ozogamicin for untreated acute myeloid leukaemia
   
Cytotoxic Drug Ibrutinib (Imbruvica®)Black Triangle
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund

Restriction: In line with NICE Guidance only

 

MHRA/CHM advice: Ibrutinib (Imbruvica®): reports of ventricular tachyarrhythmia; risk of hepatitis B reactivation and of opportunistic infections (August 2017)

 
Link  NICE TA429 : Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation
Link  NICE TA491: Ibrutinib for treating Waldenstrom’s macroglobulinaemia
Link  NICE TA502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma
   
Cytotoxic Drug Idelalisib (Zydelig®)Black Triangle
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
NHS England

Restriction: In line with NICE Guidance only

 

MHRA/CHM advice: Idelalisib (Zydelig®): Updated indications and advice on minimising the risk of infection (September 2016)

 
Link  NICE TA359: Idelalisib for treating chronic lymphocytic leukaemia
   
Cytotoxic Drug Imatinib mesilate 
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
NHS England

Restriction: In line with NICE Guidance only

 

 

 
Link  NICETA70: Guidance on the use of imatinib for chronic myeloid leukaemia
Link  NICE TA86: Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours
Link  NICE TA209: Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours
Link  NICE TA326: Imatinib for the adjuvant treatment of gastrointestinal stromal tumours
Link  NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Link  NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
   
Cytotoxic Drug Inotuzumab ozogamicin
(Besponsa®)Black Triangle
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund

Restriction: In line with NICE Guidance only

 
Link  NICE TA541: Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia
   
Ipilimumab (Yervoy®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England

Restriction: In line with NICE Guidance only

 

 

 
Link  MHRA advice (Jan 2019) - Ipilimumab (Yervoy): reports of cytomegalovirus (CMV) gastrointestinal infection or reactivation
Link  NICE TA268: Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma
Link  NICE TA319: Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma
Link  NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma
Link  NICE TA581: Nivolumab with ipilimumab for untreated advanced renal cell carcinoma
   
Cytotoxic Drug Ixazomib (Ninlaro®)Black Triangle
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England

Restriction: In line with NICE Guidance only

 
Link  NICE TA505: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma
   
Cytotoxic Drug Lenvatinib Black Triangle
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England

Restriction: In line with NICE Guidance only

 
Link  NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
Link  NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
Link  NICE TA551: Lenvatinib for untreated advanced hepatocellular carcinoma
   
Lorlatinib 
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England

Restriction: In line with NICE Guidance only

 

 
Link  NICE TA628: Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer
   
Midostaurin (Rydapt ®)Black Triangle
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund

Restriction: In line with NICE Guidance only

 
Link  NICE TA523: Midostaurin for untreated acute myeloid leukaemia
   
Cytotoxic Drug Nilotinib (Tasigna®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England

Restriction: In line with NICE Guidance only

 

MHRA/CHM advice (May 2016): Risk of hepatitis B virus reactivation with tyrosine kinase inhibitors

 
Link  NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Link  NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
   
Cytotoxic Drug Nintedanib esilate Black Triangle
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
NHS England

Restriction: In line with NICE Guidance only

 
Link  NICE TA347:Nintedanib for previously treated locally advancedm,metastatic, or locally recurrent non‑small‑cell lung cancer
Link  NICE TA379:Nintedanib for treating idiopathic pulmonary fibrosis
   
Cytotoxic Drug Niraparib (Zejula®)Black Triangle
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund

Restriction: In line with NICE Guidance only

 
Link  NICE TA528: Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer
   
Nivolumab (Opdivo®)Black Triangle
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England

Restriction: In line with NICE Guidance only

 

MHRA advice (Oct 2019): Nivolumab (Opdivo): reports of cytomegalovirus (CMV) gastrointestinal infection or reactivation

 
Link  NICE TA384: Nivolumab for treating advanced (unresectable or metastatic) melanoma
Link  NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma
Link  NICE TA417: Nivolumab for previously treated advanced renal cell carcinoma
Link  NICE TA462 : Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma
Link  NICE TA483: Nivolumab for previously treated squamous non-small-cell lung cancer
Link  NICE TA484: Nivolumab for previously treated non-squamous non-small-cell lung cancer
Link  NICE TA490: Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy
Link  NICETA558: Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease
Link  NICE TA581:Nivolumab with ipilimumab for untreated advanced renal cell carcinoma
   
Cytotoxic Drug Olaparib (Lynparza®)
View adult BNF View SPC online  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England

Restriction: In line with NICE Guidance only


MHRA/CHM advice: Lynparza® (olaparib): Risk of medication errors with new pharmaceutical form (May 2018)

 
Link  MHRA/CHM drug safety update: Lynparza® (olaparib): Risk of medication errors with new pharmaceutical form (May 2018)
Link  NICE TA598: Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy
Link  NICE TA620: Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer
   
Cytotoxic Drug Olaratumab (Lartruvo®)Black Triangle
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England

Restriction: In line with NICE Guidance only

 

MHRA advice (June 2019): Lartruvo▼ (olaratumab)- withdrawal of the EU marketing authorisation due to lack of efficacy; No new patients should be started on olaratumab therapy.

 
Link  NICE TA465: Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma
   
Cytotoxic Drug Osimertinib (Tagrisso®)Black Triangle
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England

Restriction: In line with NICE Guidance only

 
Link  NICE TA416: Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer
   
Cytotoxic Drug Oxaliplatin 
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine

Restriction: In line with NICE Guidance only

 
Link  NICE TA100: Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes’ C) colon cancer
   
Cytotoxic Drug Paclitaxel 
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
NHS England

Restriction: In line with NICE Guidance only

 
Link  NICE TA108: Breast cancer (early) - paclitaxel
Link  NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Link  NICE TA476: Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer
   
Cytotoxic Drug Palbociclib (Ibrance®)Black Triangle
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England

Restriction: In line with NICE Guidance only

 
Link  NICE TA495: Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative,
Link  NICE TA619: Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer
   
Cytotoxic Drug Panitumumab (Vectibix®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England

Restriction: In line with NICE Guidance only

 

MHRA/CHM advice: Severe skin reactions

MHRA/CHM advice: Epidermal growth factor receptor (EGFR) inhibitors: serious cases of keratitis and ulcerative keratitis (May 2012)

 
Link  NICE TA439 : Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
   
Cytotoxic Drug Panobinostat (Farydak®)Black Triangle
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England

Restriction: In line with NICE Guidance only

 
Link  NICE TA380: Panobinostat for treating multiple myeloma after at least 2 previous treatments
   
Cytotoxic Drug Pazopanib (Votrient®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
NHS England

Restriction: In line with NICE Guidance only

 
Link  NICE TA215: Pazopanib for the first-line treatment of advanced renal cell carcinoma
   
Cytotoxic Drug Pegaspargase (Oncaspar®)Black Triangle
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
NHS England

Restriction: In line with NICE Guidance only

 
Link  NICE TA408: Pegaspargase for treating acute lymphoblastic leukaemia
   
Pembrolizumab (Keytruda®)Black Triangle
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England

Restriction: In line with NICE Guidance only

 

MHRA/CHM advice: Pembrolizumab (Keytruda®): reports of organ transplant rejection (July 2017)

 
Link  NICE TA357: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab
Link  NICE TA366: Pembrolizumab for advanced melanoma not previously treated with ipilimumab
Link  NICE TA428: Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy
Link  NICE TA519: Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
Link  NICE TA522: Pembrolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
Link  NICE TA531: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer
Link  NICE TA540: Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma
Link  NICE TA553: Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence
Link  NICE TA557: Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer
Link  NICE TA600: Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer
   
Cytotoxic Drug Pertuzumab (Perjeta®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England

Restriction: In line with NICE Guidance only

 
Link  NICE TA424: Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer
Link  NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
Link  NICE TA569: Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer
   
Cytotoxic Drug Ponatinib (Iclusig®)Black Triangle
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England

Restriction: In line with NICE Guidance only

 

MHRA/CHM advice: Ponatinib: risk of vascular occlusive events—updated advice on possible dose reduction (updated April 2017)

MHRA/CHM advice: Risk of hepatitis B virus reactivation with BCR-ABL tyrosine kinase inhibitors (May 2016)

MHRA/CHM advice: Ponatinib (Iclusig®): reports of posterior reversible encephalopathy syndrome (October 2018)

 
Link  NICE TA451 : Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia
   
Cytotoxic Drug Regorafenib (Stivarga® )
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England

Restriction: In line with NICE Guidance only

 
Link  NICE TA488: Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours
Link  NICE TA555: Regorafenib for previously treated advanced hepatocellular carcinoma
   
Cytotoxic Drug Ribociclib succinate
(Kisqali®)Black Triangle
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England

Restriction: In line with NICE Guidance only

 
Link  NICE TA496: Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Link  NICE TA593: Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer
   
Cytotoxic Drug Ruxolitinib phosphate
(Jakavi®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England

Restriction: In line with NICE Guidance only

 
Link  NICE TA386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis
   
Cytotoxic Drug Sorafenib tosylate (Nexavar®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
NHS England

Restriction: In line with NICE Guidance only

 
Link  NICE TA474: Sorafenib for treating advanced hepatocellular carcinoma
Link  NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
   
Cytotoxic Drug Sunitinib (Sutent®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England

Restriction: In line with NICE Guidance only

 
Link  NICE TA169: Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma
Link  NICE TA179: Sunitinib for the treatment of gastrointestinal stromal tumours
Link  NICE TA449 : Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
   
Talimogene laherparepvac
(Imlygic®)Black Triangle
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England

Restriction: In line with NICE Guidance only

 
Link  NICE TA410:Talimogene laherparepvec for treating unresectable metastatic melanoma
   
Cytotoxic Drug Temozolomide 
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine

Restriction: In line with NICE Guidance only

 

This is a Specialised Drug which would not be routinely commissioned by CCGs for Endocrinology: non-malignant conditions. This would go through CCGs Individual Funding Request (IFR).

 
Link  NICE TA121: Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma
Link  NICE TA23: Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer)
   
Tisagenlecleucel (Kymriah®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England

Restriction: In line with NICE guideline only

 
Link  NICE TA 567: Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies
Link  NICE TA554: Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years
   
Cytotoxic Drug Tivozanib (Fotivda®)Black Triangle
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England

Restriction: In line with NICE Guidance only

 
Link  NICE TA512: Tivozanib for treating advanced renal cell carcinoma
   
Cytotoxic Drug Topotecan (Hycamtin®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine

Restriction: In line with NICE Guidance only

 
Link  NICE TA183: Topotecan for the treatment of recurrent and stage IVB cervical cancer
Link  NICE TA184:Topotecan for the treatment of relapsed small-cell lung cancer
Link  NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
   
Cytotoxic Drug Trabectedin (Yondelis®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
NHS England

Restriction: In line with NICE Guidance only

 
Link  NICE TA185: Trabectedin for the treatment of advanced soft tissue sarcoma
Link  NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
   
Cytotoxic Drug Trametinib (Mekinist®)Black Triangle
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England

Restriction: In line with NICE Guidance only

 
Link  NICE TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
Link  NICE TA544; Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma
   
Cytotoxic Drug Trastuzumab 
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England

Restriction: In line with NICE Guidance only

 

 
Link  NICE TA34: Guidance on the use of trastuzumab for the treatment of advanced breast cancer
Link  NICE NG101: Early and locally advanced breast cancer: diagnosis and management
Link  NICE TA208: Trastuzumab for the treatment of HER2-positive metastatic gastric cancer
Link  NICE TA458: Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane
Link  NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
   
Cytotoxic Drug Trifluridine-tipiracil
(Lonsurf®)Black Triangle
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England

Restriction: In line with NICE Guidance only

 
Link  NICE TA405: Trifluridine–tipiracil for previously treated metastatic colorectal cancer
   
Cytotoxic Drug Vemurafenib (Zelboraf®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
NHS England

Restriction: In line with NICE Guidance only

 

Drug rash with eosinophilia and systemic symptoms (DRESS syndrome)

MHRA/CHM advice (November 2015): Risk of potentiation of radiation toxicity

 
Link  NICE TA269: Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanoma
   
Cytotoxic Drug Venetoclax (Venclyxto®)Black Triangle
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
Cancer Drugs Fund
NHS England

Restriction: In line with NICE Guidance only

 
Link  NICE TA487: Venetoclax for treating chronic lymphocytic leukaemia
Link  NICE TA561: Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia
   
 ....
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG
Blueteq
High Cost Drug Approval System

Traffic Light Status Information

Status Description

Red

Medicines that can only be prescribed within Secondary Care. Examples of medicines which fall into this category are: Certain new medicines and new indications for older medicines where there is at present no experience of use in Primary Care. Medicines or dressings not available or prescribable in Primary Care. Where a medicine has been classified as Amber E, but an approved shared-care guideline is not yet available   

Amber

Medicines which can be prescribed within Secondary Care, but are only suitable for prescribing in Primary Care after specialist referral. There is no need for approved shared care guidelines for medicines in this category. This replaces Amber 2 on the North Staffs Formulary.   

Amber E

Medicines which can be prescribed within Secondary Care, but are only considered suitable for prescribing in Primary Care under an approved shared-care agreement (ESCA) or Rationale for Initiation, Continuation and Discontinuation (RICaD). This replaces Amber 1 on the North Staffs Formulary  

Green

Medicines which can be prescribed in either Primary or Secondary Care.  

Grey

These medicines have been reviewed by the New Medicines Committee and the Area Prescribing Committee and found not to be suitable for inclusion in the Joint Formulary. Inadequate or weak evidence for efficacy No clearly defined local need Lack of long term safety data No perceived benefit over established formulary alternatives Prescribers can consider these medicines where formulary alternatives are unsuitable, ineffective or not tolerated.  

netFormulary